On Thursday, Vir Biotechnology (NASDAQ: NASDAQ:VIR) stock received an upgrade from Morgan Stanley (NYSE:MS), changing its rating from Equalweight to Overweight. The firm also significantly increased the company's price target to $20.00, up from the previous $10.00. The upgrade comes as the stock has shown remarkable momentum, with InvestingPro data showing a 71.66% return over the past week.
While the stock currently trades at $12.48, InvestingPro analysis suggests it may be trading above its Fair Value. This adjustment comes in light of the encouraging preliminary results from Vir's T-cell engager (TCE) pipeline. Morgan Stanley's analysts have expressed confidence in the platform's potential, citing the inclusion of projected revenues from the VIR-5500 program, which targets prostate cancer, as a key factor in their revised valuation.
The analysts at Morgan Stanley have adjusted their financial model for Vir Biotechnology, accounting for several factors. They incorporated expected revenues from the VIR-5500 program while simultaneously reducing operating expenses (OpEx) projections to align with the company's updated cash guidance.
According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 8.94 and holds more cash than debt on its balance sheet, though it's worth noting the company is currently burning through cash rapidly. This reduction in OpEx is estimated to add approximately $4 per share to the price target. However, the analysts also removed projected revenues from Hepatitis B treatments from their model, which they note would decrease the price target by $1 per share.
Despite the removal of Hepatitis B revenues, the overall impact of these adjustments is positive, leading to the doubling of the price target. The inclusion of VIR-5500 revenues is estimated to contribute an additional $7 per share to the price target. The net effect of these changes has resulted in the price target being raised to $20 from the previous estimate of $10.
The upgrade to an Overweight rating suggests that Morgan Stanley expects Vir Biotechnology's stock to outperform the average return of the stocks the analyst covers over the next 12 to 18 months. The new price target of $20 indicates a significant increase in the firm's valuation of the biotechnology company's shares.
Morgan Stanley's decision to upgrade Vir Biotechnology's stock and raise the price target reflects their analysts' optimistic view on the company's financial outlook and the potential success of its TCE pipeline, particularly the VIR-5500 program for prostate cancer. InvestingPro subscribers can access 12 additional exclusive tips and comprehensive analysis through the Pro Research Report, which provides deeper insights into Vir's financial health score of FAIR and its market position among 1,400+ top US stocks.
With the updated cash guidance and the strategic adjustments made to their revenue model, Morgan Stanley has conveyed a strong vote of confidence in Vir Biotechnology's future performance.
In other recent news, Vir Biotechnology has been receiving positive reviews from major financial firms due to promising developments in its clinical programs.
Goldman Sachs maintained a Buy rating on the company with a steady price target of $28, while JPMorgan raised its stock target from $10 to $14, maintaining a Neutral rating. TD Cowen also kept its Buy rating, highlighting the potential of Vir's pipeline programs, particularly its treatments for hepatitis B and D.
These ratings follow Vir's recent updates on its T cell engager programs, licensed from Sanofi (NASDAQ:SNY), which show early signs of differentiation from competitors. Moreover, the company's investigational drugs, tobevibart and elebsiran, have received Breakthrough Therapy designation by the FDA and Priority Medicines designation by the EMA for the treatment of chronic hepatitis delta.
Furthermore, Vir Biotechnology's treatments for chronic hepatitis delta have received a positive opinion for orphan drug designation from the EMA. The company also shared encouraging results from a Phase 2 clinical trial for chronic hepatitis B treatment and significant developments during its third-quarter 2024 earnings call.
These recent developments underscore Vir Biotechnology's commitment to advancing its clinical programs, particularly in the areas of oncology and hepatitis. The company's T-cell engager programs are progressing with Phase I trials ongoing and initial data expected soon.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.